Clinical Application of RLT Discussed between Shanghai General Hospital and Novartis International Team

https://mp.weixin.qq.com/s/edFbc0sJCoy-2eZxefzhjQ

The world's first radioactive ligand therapy targeting prostate cancer, 177Lu-PSMA-617, is currently undergoing smooth clinical trials in China and is expected to be launched domestically, bringing new hope to patients with metastatic prostate cancer. Unlike traditional drugs, innovative nuclear drugs represented by radioligand therapy (RLT) face more complex processes and stricter challenges in terms of production, preparation, transportation, clinical use and patient management.

On the morning of May 22, 2024, Rudy Cohen, Head of International Customer Strategy and Operations at Novartis, Mark Farnworth, Director of International Strategy and Engagement at Novartis, Jacqueline Hauptmann, Deputy Director of International Strategy and Engagement at Novartis, Panagiota Papaioannou, Deputy Director of Healthcare System Partnerships at Novartis, Ahmed Zayan, Global Head of Radioligand Therapy Supply Strategy at Novartis, and their team visited the Nuclear Medicine Department of Shanghai General Hospital. They discussed with Professor Xing Yan, the Deputy Director of the Nuclear Medicine Department, about standardizing the clinical pathway for the application of radioligand drugs, optimizing the use process of radioligand drugs, and other related issues.

As a significant participant in the clinical trial of 177Lu-PSMA-617, Shanghai General Hospital has undertaken clinical research on prostate cancer patients with two different disease stages, mCRPC and mHSPC, and conducted the first treatment of 177Lu-PSMA-617 on prostate cancer patients in Shanghai. Currently, all subjects have been enrolled. Mr. Rudy Cohen and his team also visited the intelligent radionuclide ward of the Nuclear Medicine Department, where they learned about the latest radionuclide treatment model. They highly praised the experience gained by the Nuclear Medicine Department of Shanghai General Hospital in standardizing the logistics, reception, drug administration, radiation protection, and monitoring of radioactive ligand therapy. They expressed their hope for deeper cooperation and exchanges in the future, aiming to bring the benefits of radioactive ligand therapy to Chinese patients as soon as possible.